Community Oncology Alliance (COA)

Community Oncology Alliance (COA) submitted formal comments to CMS in support of proposed changes to the 340B Drug Discount Program and site-neutral paymnts put forward in the Hospital Outpatient Prospective Payment (HOPPS) rule. However, they also submitted comments warning against proposals to introduce new third-party middlemen to the Part B system.

Community Oncology Alliance (COA) has submitted formal comments to CMS Administrator Seema Verma on the 2019 Medicare Physician Fee Schedule.

The Community Oncology Alliance (COA) announced their support of CMS’ 2019 Outpatient Prospective Payment System (OPPS) Proposed Rule.

Following CMS’ announcement of proposed rules for the 2019 Medicare Physician Fee Schedule, Community Oncology Alliance (COA) released a statement calling the proposals “puzzling.” The statement details concern with 2 proposals.

The Community Oncology Alliance (COA) has voiced its support of the 340B Drug Discount Accountability Act, which would require hospitals to report their total 340B drug purchases and pay a small 0.1% user fee to the Health Resources and Services Administration.

The Community Oncology Alliance (COA) has filed a lawsuit in the US District Court for the District of Columbia, stating that the 2% sequester cut to Medicare Part B drug reimbursement is unconstitutional and illegal, and that it can harm patient care and have a huge impact on the communityc ancer care system.

In a survey released by Community Oncology Alliance (COA), the majority of physicians reported concern over proposals to reform the Medicare Part B program

In response to President Donald Trump's blueprint on lowering drug prices and reducing out-of-pocket costs, Community Oncology Alliance (COA) commended the administration for working to put patients first and lower prices, while also urging caution for unintended consequences.